Shanghai-based Junshi Biosciences has announced a partnership with Denmark’s LEO Pharma to distribute and commercialise the ...

The certification covers the company’s manufacturing facility for cephalosporin, carbapenem, and lyophilized injectable ...

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of multiple malignant tumors. To date, toripalimab has been approved for marketing ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / ...

The US could be the beneficiary of a potential blanket ban on the use of PFAS, better known as ‘forever chemicals’.

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...

Leading pharmaceutical and IT companies have said they will quit Ireland if a proposed ban on so-called forever chemicals is ...

Red No. 3, a synthetic dye that gives a cherry hue to candies, sodas, and some medications, has been linked to cancer in some ...

Scaling personalized therapies brings unique logistical challenges. Unlike mass-market drugs, these treatments require highly specific materials, stringent cold chain logistics and real-time ...